基于经导管动脉化疗栓塞联合治疗肝癌伴门静脉癌栓的进展  

Progress in the treatment of liver cancer with portal vein thrombosis based on TACE

作　　者：崔皓然 顾俊鹏[1] 任伟新[1] Cui Haoran;Gu Junpeng;Ren Weixin(Department of Interventional Radiology,the First Affiliated Hospital of Xinjiang Medical University,Xinjiang Urmqi 830054,China)

机构地区：[1]新疆医科大学第一附属医院介入放射科,新疆乌鲁木齐830054

出　　处：《中华介入放射学电子杂志》2024年第1期64-69,共6页Chinese Journal of Interventional Radiology：electronic edition

基　　金：新疆维吾尔自治区科技支疆项目计划(指令性)项目(2021E02074)。

摘　　要：肝细胞癌是最常见的恶性肿瘤之一,在确诊时就属于中晚期的阶段,一半以上患者伴有门静脉癌栓,在不进行相关干预治疗的情况下,中位生存期约为2.7个月。对于该类患者治疗方式的选择,我国还未有一致的共识,传统的治疗方式,如手术切除、肝移植、放射及靶向治疗等,效果仍不理想;伴随介入治疗的发展,以经导管动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)为基础的联合治疗方案效果显著。本文将系统概述肝癌合并门脉癌栓的临床诊断、病理分型及以TACE为基础联合其他治疗方式的研究进展,为以后的临床工作提供参考。Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Patients usually are diagnosed in the middle/advanced stage of HCC and more than half of the patients are accompanied by portal vein tumor thrombosis(PVTT).Without relevant intervention and treatment,the median survival period is about 2.7 months.There is no consensus in China on the choice of treatment methods for these patients.Traditional treatment methods,such as surgical treatment,liver transplantation,radiation therapy and targeted therapy still have unsatisfactory results.With the development of interventional treatment,the combined treatment based on transcatheter arterial chemoembolization(TACE)has shown significant efficacy.In this paper,the clinical diagnosis and pathological classification of hepatocellular carcinoma with portal vein tumor thrombosis and the research progress of TACE based combined with other therapy methods are summarized systematically,so as to provide reference for future clinical work.

关 键 词：肝细胞癌 门静脉癌栓 经导管动脉化疗栓塞介入治疗 

分 类 号：R735.7[医药卫生—肿瘤]